KR100828957B1 - 안정화된 비경구 투여용 수성 현탁액 - Google Patents

안정화된 비경구 투여용 수성 현탁액 Download PDF

Info

Publication number
KR100828957B1
KR100828957B1 KR1020027015431A KR20027015431A KR100828957B1 KR 100828957 B1 KR100828957 B1 KR 100828957B1 KR 1020027015431 A KR1020027015431 A KR 1020027015431A KR 20027015431 A KR20027015431 A KR 20027015431A KR 100828957 B1 KR100828957 B1 KR 100828957B1
Authority
KR
South Korea
Prior art keywords
formulation
concentration
delete delete
biologically active
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027015431A
Other languages
English (en)
Korean (ko)
Other versions
KR20030020280A (ko
Inventor
콜롬보기우세페
마르티니알레산드로
팍스로이드이
Original Assignee
파마시아 이탈리아 에스.피.에이.
파마시아 앤드 업존 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마시아 이탈리아 에스.피.에이., 파마시아 앤드 업존 캄파니 엘엘씨 filed Critical 파마시아 이탈리아 에스.피.에이.
Publication of KR20030020280A publication Critical patent/KR20030020280A/ko
Application granted granted Critical
Publication of KR100828957B1 publication Critical patent/KR100828957B1/ko
Assigned to 파이저 이딸리아 에쓰.알.엘. reassignment 파이저 이딸리아 에쓰.알.엘. 권리지분의 전부이전등록 Assignors: 파마시아 이탈리아 에스.피.에이.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020027015431A 2000-05-15 2001-04-25 안정화된 비경구 투여용 수성 현탁액 Expired - Lifetime KR100828957B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/571,395 US6495534B2 (en) 2000-05-15 2000-05-15 Stabilized aqueous suspensions for parenteral use
US09/571,395 2000-05-15
PCT/EP2001/004643 WO2001087266A1 (en) 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use

Publications (2)

Publication Number Publication Date
KR20030020280A KR20030020280A (ko) 2003-03-08
KR100828957B1 true KR100828957B1 (ko) 2008-05-13

Family

ID=24283530

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027015431A Expired - Lifetime KR100828957B1 (ko) 2000-05-15 2001-04-25 안정화된 비경구 투여용 수성 현탁액

Country Status (30)

Country Link
US (3) US6495534B2 (https=)
EP (1) EP1282402B1 (https=)
JP (1) JP4205341B2 (https=)
KR (1) KR100828957B1 (https=)
CN (1) CN100473376C (https=)
AR (3) AR029924A1 (https=)
AT (1) ATE313316T1 (https=)
AU (2) AU2001267371B2 (https=)
BR (1) BR0110841A (https=)
CA (1) CA2409059C (https=)
CZ (1) CZ303872B6 (https=)
DE (1) DE60116084T2 (https=)
DK (1) DK1282402T3 (https=)
EA (1) EA007682B1 (https=)
EE (1) EE05376B1 (https=)
ES (1) ES2254443T3 (https=)
HK (1) HK1054194B (https=)
HU (1) HU229800B1 (https=)
IL (2) IL152537A (https=)
IN (1) IN224279B (https=)
MX (1) MXPA02011195A (https=)
NO (1) NO332215B1 (https=)
NZ (1) NZ522324A (https=)
PE (1) PE20011322A1 (https=)
PL (1) PL203075B1 (https=)
SI (1) SI1282402T1 (https=)
SK (1) SK287641B6 (https=)
TW (1) TWI256310B (https=)
WO (1) WO2001087266A1 (https=)
ZA (1) ZA200208738B (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
WO2004018312A1 (en) 2002-08-21 2004-03-04 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
US20050054716A1 (en) * 2002-11-08 2005-03-10 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
DE602004015755D1 (de) * 2003-03-31 2008-09-25 Alza Corp Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
JP5651279B2 (ja) * 2003-09-03 2015-01-07 ミスコン トレイディング エス．エー． 子宮内膜症の処置のための方法
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
CA2581076A1 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
JP2009526858A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー コルチコステロイド溶液を製造する方法
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP5371180B2 (ja) * 2006-06-15 2013-12-18 日立コンシューマエレクトロニクス株式会社 投写型映像表示装置
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
JP5624766B2 (ja) * 2006-09-27 2014-11-12 イーグル・ファーマシューティカルズ・インコーポレーテッド アルコールを含まないアルガトロバン製剤
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
GB0625962D0 (en) * 2006-12-23 2007-02-07 Renovo Ltd Medicaments and methods for wound healing
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
US8287729B2 (en) * 2008-04-28 2012-10-16 California Polytechnic Corporation Field water purification system
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
CN106442039B (zh) 2011-06-19 2020-08-07 阿博根公司 用于样品采集的装置、溶液和方法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
UA74095U (ru) * 2012-07-20 2012-10-10 Николай Иванович Гуменюк Препарат для лечения туберкулеза
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9649353B2 (en) 2013-09-17 2017-05-16 Terapio Corporation Methods of preventing or treating mucositis by administering RLIP76
CN104706578B (zh) * 2013-12-14 2019-04-23 天津金耀集团有限公司 一种醋酸甲泼尼龙混悬注射液组合物的制备方法
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US9907449B2 (en) 2015-03-16 2018-03-06 Irobot Corporation Autonomous floor cleaning with a removable pad
US9265396B1 (en) 2015-03-16 2016-02-23 Irobot Corporation Autonomous floor cleaning with removable pad
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3423036B1 (en) 2016-03-02 2022-01-26 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
SI3943070T1 (sl) 2017-07-14 2024-03-29 Janssen Pharmaceutica Nv, Dolgo delujoče formulacije bedakilina
US20200281939A1 (en) * 2017-09-07 2020-09-10 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
WO2019048906A1 (en) * 2017-09-07 2019-03-14 Teva Pharmaceutical Industries Ltd. INJECTABLE COMPOSITIONS OF MEDROXYPROGESTERONE ACETATE AND METHODS OF USE
EP3706719A1 (en) 2017-11-08 2020-09-16 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
WO2019140032A1 (en) 2018-01-11 2019-07-18 Meritage Pharma, Inc. Stable corticosteroid compositions
EP3846777B1 (en) 2018-09-07 2025-12-10 Family Health International Medroxyprogesterone acetate injectable compositions and methods of use
US10544923B1 (en) 2018-11-06 2020-01-28 Verifone, Inc. Devices and methods for optical-based tamper detection using variable light characteristics
US11712692B2 (en) 2018-11-20 2023-08-01 Spectrum Solutions L.L.C. Sample collection system including sealing cap and valve
IT201900002857A1 (it) * 2019-02-27 2020-08-27 Ntc S R L Procedimento di riempimento di contenitori con una polvere
US11701094B2 (en) 2019-06-20 2023-07-18 Spectrum Solutions L.L.C. Sample collection system including valve and plug assemblies
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
TW202239408A (zh) * 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
US20240237929A1 (en) * 2021-05-19 2024-07-18 Acies Medical Llc Point-of-use calibration system for iron ion detection system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015193A1 (de) * 1997-09-23 1999-04-01 Rentschler Biotechnologie Gmbh & Co. Kg FLÜSSIGE INTERFERON-β-FORMULIERUNGEN

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
JP2577744B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
ATE99943T1 (de) 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
JPH0597671A (ja) 1991-10-04 1993-04-20 Sumitomo Pharmaceut Co Ltd 注射用凍結乾燥製剤
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3543144B2 (ja) 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
AU4344697A (en) 1996-10-04 1998-04-24 Amgen, Inc. Pharmaceutical compositions containing an mpl ligand
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP3748970B2 (ja) 1997-01-31 2006-02-22 電気化学工業株式会社 ヒアルロン酸ナトリウム含有水溶液
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO1999051237A1 (en) 1998-04-02 1999-10-14 Akzo Nobel N.V. Oral liquid antidepressant solution
DE60031999T2 (de) 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015193A1 (de) * 1997-09-23 1999-04-01 Rentschler Biotechnologie Gmbh & Co. Kg FLÜSSIGE INTERFERON-β-FORMULIERUNGEN

Also Published As

Publication number Publication date
BR0110841A (pt) 2003-03-11
AR098830A2 (es) 2016-06-15
JP2003533467A (ja) 2003-11-11
EA200201208A1 (ru) 2003-04-24
HUP0302021A3 (en) 2011-03-28
ZA200208738B (en) 2003-10-29
DE60116084T2 (de) 2006-08-17
CA2409059C (en) 2006-04-18
ES2254443T3 (es) 2006-06-16
EA007682B1 (ru) 2006-12-29
IL152537A (en) 2007-06-17
SI1282402T1 (sl) 2006-04-30
NO20025431L (no) 2003-01-13
JP4205341B2 (ja) 2009-01-07
EE05376B1 (et) 2011-02-15
NZ522324A (en) 2005-02-25
SK287641B6 (sk) 2011-05-06
WO2001087266A1 (en) 2001-11-22
AU2001267371B2 (en) 2006-01-05
HU229800B1 (en) 2014-07-28
NO332215B1 (no) 2012-07-30
DK1282402T3 (da) 2006-05-08
CN100473376C (zh) 2009-04-01
CN1429101A (zh) 2003-07-09
PL365793A1 (en) 2005-01-10
CA2409059A1 (en) 2001-11-22
SK15982002A3 (sk) 2003-05-02
IN224279B (https=) 2005-02-25
CZ303872B6 (cs) 2013-06-05
PL203075B1 (pl) 2009-08-31
EE200200631A (et) 2004-04-15
CZ20023750A3 (cs) 2003-03-12
DE60116084D1 (de) 2006-01-26
US20030114430A1 (en) 2003-06-19
NO20025431D0 (no) 2002-11-13
EP1282402B1 (en) 2005-12-21
IL165888A0 (en) 2006-01-15
HK1054194B (zh) 2010-02-12
KR20030020280A (ko) 2003-03-08
AR029924A1 (es) 2003-07-23
PE20011322A1 (es) 2002-01-10
ATE313316T1 (de) 2006-01-15
US20020115645A1 (en) 2002-08-22
AR111695A2 (es) 2019-08-07
TWI256310B (en) 2006-06-11
US20030130245A1 (en) 2003-07-10
US6495534B2 (en) 2002-12-17
AU6737101A (en) 2001-11-26
HUP0302021A2 (hu) 2003-09-29
MXPA02011195A (es) 2003-03-10
EP1282402A1 (en) 2003-02-12
HK1054194A1 (zh) 2003-11-21
IL152537A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
KR100828957B1 (ko) 안정화된 비경구 투여용 수성 현탁액
AU2001267371A1 (en) Stabilized aqueous suspensions for parenteral use
KR100486146B1 (ko) 치료용시스플라틴(cddp)를위한방법및조성물
KR101053780B1 (ko) 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
US6025396A (en) Stable prostaglandin E1-containing injectable composition
EP1352654B1 (en) Famotidine injections
US20030165568A1 (en) Stabilized steroidal suspension
WO2021224902A2 (en) An improved process for the preparation of an aqueous ophthalmic solution of difluprednate
WO2022034614A1 (en) Phytonadione compositions
WO2024224373A1 (en) Levothyroxine dispersions
WO2023017326A1 (en) Ready to use compositions of cetrorelix acetate

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060713

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070425

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20071012

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20070425

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20060713

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080111

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20071012

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080222

Appeal identifier: 2008101000230

Request date: 20080111

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080111

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080111

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070625

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070112

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20050224

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20080222

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20080212

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080506

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080507

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110428

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20120427

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130429

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130429

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140430

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140430

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160330

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20190327

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20200324

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20211025

Termination category: Expiration of duration